Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.

OBJECTIVE Three anti-tumor necrosis factor alpha (anti-TNFalpha) agents have been proved to be effective for rheumatoid arthritis (RA) and other inflammatory disorders. Infliximab and adalimumab have been generated as anti-TNFalpha monoclonal antibodies, while etanercept is engineered from human type II TNF receptors. In spite of all 3 agents' equal efficacy for RA, both infliximab and adalimumab are effective for other diseases such as Crohn's disease and Wegener's granulomatosis, while etanercept is not. We undertook this study to understand the different clinical effects of these anti-TNFalpha agents by analyzing their biologic activities on transmembrane TNFalpha. METHODS Jurkat T cells stably expressing an uncleavable form of transmembrane TNFalpha were used for the following studies: 1) flow cytometric analysis of binding activities of anti-TNF agents to cell surface transmembrane TNFalpha, 2) complement-dependent cytotoxicity (CDC), 3) antibody-dependent cell-mediated cytotoxicity (ADCC) by using peripheral blood mononuclear cells, and 4) outside-to-inside (reverse) signal transduction through transmembrane TNFalpha estimated by apoptosis and cell cycle analysis using flow cytometry. RESULTS All of the anti-TNFalpha agents bound to transmembrane TNFalpha. Infliximab and adalimumab exerted almost equal CDC activities, while etanercept showed considerably lower activity. ADCC activities were almost equal among these 3 agents. Adalimumab and infliximab induced apoptosis and cell cycle arrest in transmembrane TNFalpha-expressing Jurkat T cells, reflecting an outside-to-inside signal transduction through transmembrane TNFalpha. CONCLUSION Three different anti-TNF agents showed different biologic effects on transmembrane TNFalpha. This finding suggests that CDC and outside-to-inside signals by anti-TNFalpha antibodies may explain the successful clinical efficacy of adalimumab and infliximab in Crohn's disease and Wegener's granulomatosis.

[1]  T. Horiuchi,et al.  Membrane Tumor Necrosis Factor-α (TNF-α) Expressed on HTLV-I-Infected T Cells Mediates a Costimulatory Signal for B Cell Activation—Characterization of Membrane TNF-α , 1997 .

[2]  M. Carroll,et al.  Identification of a major binding site for complement C3 on the IgG1 heavy chain. , 1993, The Journal of biological chemistry.

[3]  Takahiko Horiuchi,et al.  Outside-to-Inside Signal Through the Membrane TNF-α Induces E-Selectin (CD62E) Expression on Activated Human CD4+ T Cells1 , 2001, The Journal of Immunology.

[4]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[5]  B. Scallon,et al.  Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[6]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[7]  Warwick J. Britton,et al.  Transmembrane TNF Is Sufficient to Initiate Cell Migration and Granuloma Formation and Provide Acute, but Not Long-Term, Control of Mycobacterium tuberculosis Infection1 , 2005, The Journal of Immunology.

[8]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[9]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[10]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[11]  P. Rutgeerts,et al.  Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model , 2006, Inflammatory bowel diseases.

[12]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[13]  V. Roschke,et al.  Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. , 2003, Arthritis and rheumatism.

[14]  T. Horiuchi,et al.  Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.

[15]  R. Luqmani,et al.  Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis , 2005 .

[16]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[17]  T. Decker,et al.  Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. , 1987, Journal of immunology.

[18]  R. Wilkinson,et al.  Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. , 2001, Journal of immunological methods.

[19]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[20]  W. Fiers,et al.  Two tumour necrosis factor receptors: structure and function. , 1995, Trends in cell biology.

[21]  Reto Guler,et al.  Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. , 2005, The American journal of pathology.

[22]  C. Dinarello.  Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. , 2005, The Journal of rheumatology. Supplement.

[23]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[24]  T. Horiuchi,et al.  Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. , 2004, Gastroenterology.

[25]  M. Cragg,et al.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.

[26]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[27]  J. Bonnefoy,et al.  Human NK cells constitutively express membrane TNF‐α (mTNFα) and present mTNFα‐dependent cytotoxic activity , 1999 .

[28]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[29]  D. Wallach,et al.  Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. , 1995, Journal of inflammation.

[30]  M. Cragg,et al.  The biology of CD20 and its potential as a target for mAb therapy. , 2005, Current directions in autoimmunity.

[31]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[32]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[33]  Walter Kolch,et al.  Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. , 2004, Cytokine & growth factor reviews.

[34]  C. Perez,et al.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF , 1988, Cell.

[35]  Kenshi Hayashi,et al.  Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. , 2002, Blood.

[36]  N. Olsen,et al.  New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.

[37]  W. Sandborn,et al.  CLASSIC-I study the efficacy of adalimumab. , 2006, Gastroenterology.

[38]  M. Feldmann,et al.  Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. , 1997, Journal of immunology.

[39]  T. Brunner,et al.  Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. , 2004, Gastroenterology.

[40]  P. Rutgeerts,et al.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. , 1999, Gastroenterology.

[41]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .